Redmile Group PLRX Position
Active8-Fund ConvergenceRedmile Group increased their position in Pliant Therapeutics Inc. (PLRX) in Q4 2025, holding $2.0M worth of shares across 1,616,228 shares.
The position was first reported in Q1 2023 and has been tracked across 12 quarterly 13F filings.
PLRX is a convergence signal: 8 specialist biotech funds hold this stock, suggesting high institutional conviction.
About Pliant Therapeutics Inc.
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Full company profile →Short Interest
6.3%
6.0 days to cover
Redmile Group PLRX Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Increased | 1,616,228 | +24,533 | $2.0M |
| Q3 2025 | Decreased | 1,591,695 | -40,882 | $2.4M |
| Q2 2025 | Decreased | 1,632,577 | -420,982 | $1.9M |
| Q1 2025 | Decreased | 2,053,559 | -841,919 | $2.8M |
| Q4 2024 | Decreased | 2,895,478 | -302,013 | $38.1M |
| Q3 2024 | Decreased | 3,197,491 | -12,100 | $35.8M |
| Q2 2024 | Increased | 3,209,591 | +112,371 | $34.5M |
| Q1 2024 | Increased | 3,097,220 | +400,572 | $46.1M |
| Q4 2023 | Increased | 2,696,648 | +18,549 | $48.8M |
| Q3 2023 | Held | 2,678,099 | — | $46.4M |
| Q2 2023 | Decreased | 2,678,099 | -247,549 | $48.5M |
| Q1 2023 | New | 2,925,648 | +2,925,648 | $77.8M |
Frequently Asked Questions
Does Redmile Group own PLRX?
Yes. As of Q4 2025, Redmile Group holds 1,616,228 shares of Pliant Therapeutics Inc. (PLRX) valued at $2.0M. This data comes from their SEC 13F filing.
How many hedge funds own PLRX?
8 specialist biotech hedge funds currently hold PLRX, including Deep Track Capital, RA Capital Management, Casdin Capital and 4 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Redmile Group first buy PLRX?
Redmile Group's position in PLRX was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Redmile Group's PLRX position increasing or decreasing?
Redmile Group increased their PLRX position in the most recent quarter, adding 24,533 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
PLRXCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Redmile GroupPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →